zona pellucida binding proteinGenealiases: SPGF66 · ZPBP1
Q-omics provides the consensus-scored ZPBP profile across patient tissues and cancer cell-line models. ZPBP expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZPBP is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZPBP RNA expression shows 9,478 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and THCA as cancer lineages where ZPBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZPBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZPBP survival associations across molecular data types. ZPBP RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZPBP RNA expression–survival associations across cancer types. High ZPBP expression shows unfavorable associations in UCEC, but favorable associations in KIRP, KIRC, BLCA, PRAD and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZPBP RNA expression.
This table summarizes ZPBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZPBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZPBP shows lower tumor expression in THCA, KIRC, KICH, KIRP, BRCA and LUAD. The THCA box plot shows higher ZPBP RNA expression in normal versus tumor tissue (log2 FC = −0.451, t-test p < 0.001).
This table shows molecular features associated with ZPBP in patient tissues and cancer cell lines. In patient samples, ZPBP shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZPBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
